<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631408</url>
  </required_header>
  <id_info>
    <org_study_id>iVRCT1_4</org_study_id>
    <nct_id>NCT02631408</nct_id>
  </id_info>
  <brief_title>Intrawound Vancomycin Powder in Spinal Fusion Surgery</brief_title>
  <acronym>iVRCT</acronym>
  <official_title>Application of Intrawound Vancomycin Powder to Reduce Surgical Site Infections in Spinal Fusion Surgery - A Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orthopedic Hospital Vienna Speising</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orthopedic Hospital Vienna Speising</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vancomycin powder (for solution for Infusion) will be investigated (off-label usage) in&#xD;
      spinal fusion surgery. The powder will be locally administered into to the wound cavity&#xD;
      before wound closure.&#xD;
&#xD;
      Hypothesis: Locally applied vancomycin powder leads to a reduction in postoperative surgical&#xD;
      site infections&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vancomycin is being widely used as an antibiotic agent for intravenous and topical use. The&#xD;
      surgical application of vancomycin powder in Austria is limited as there is no powder with&#xD;
      marketing authorization for intraoperative, intrawound usage. Previous reports widely&#xD;
      document the application of vancomycin powder for solution for infusion. The powder is not&#xD;
      soluted, but instead directly spread throughout the wound surface. Limited data is available&#xD;
      for spinal fusion surgery, mostly retrospective studies. Results were promising, but the low&#xD;
      evidence level does not allow for a conclusion regarding routine usage. Additional&#xD;
      randomized, controlled trials are necessary to further investigate this matter.&#xD;
&#xD;
      This trial aims to investigate Vancomycin powder &quot;Xellia&quot; 1000mg, which has a Marketing&#xD;
      authorization, in an off-label usage (intrawound, intraoperatively) in spinal fusion surgery.&#xD;
      The investigational medicinal product will be used unmodified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SSI rate</measure>
    <time_frame>1 year</time_frame>
    <description>Rate of superficial and deep surgical site infections (according to CDC criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>7 days</time_frame>
    <description>Course of postoperative CRP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision rate</measure>
    <time_frame>1 year</time_frame>
    <description>Revision rate due to surgical site infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Spinal Fusion Acquired</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional treatment. Routine iv. antibiotic prophylaxis only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Locally, intrawound applied vancomycin powder</description>
    <arm_group_label>Vancomycin Group</arm_group_label>
    <other_name>Vancomycin Hydrochloride, Powder for Solution for Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned TLIF (transforaminal lumbar interbody fusion) or PLIF (posterolateral lumbar&#xD;
             interbody fusion) surgery&#xD;
&#xD;
          -  TLIF/PLIF fusion length of one or two motion-segments OR&#xD;
&#xD;
          -  One motion-segment TLIF/PLIF in conjunction with one motion-segment decompression&#xD;
             surgery or microscopic disc surgery (microdiscectomy)&#xD;
&#xD;
          -  Fusions within L1 (first lumbar vertebra) through S1 (sacrum)&#xD;
&#xD;
          -  Age of 18-years or older&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative inflammatory or infectious state (C-reactive protein levels above 10mg/l)&#xD;
&#xD;
          -  Allergic to vancomycin, teicoplanin or penicillin&#xD;
&#xD;
          -  Preexisting auto-immune disease with an impaired immune system&#xD;
&#xD;
          -  Current post-traumatic vertebral injury (e.g. vertebral split fracture)&#xD;
&#xD;
          -  Preexisting Renal impairment&#xD;
&#xD;
          -  Preexisting cochlea damage&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedic Hospital Speising</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukas Panzenboeck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Orthopedic Hospital Speising</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orhopedic Hospital Speising</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>December 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Orthopedic Hospital Vienna Speising</investigator_affiliation>
    <investigator_full_name>Lukas Panzenboeck</investigator_full_name>
    <investigator_title>Dr. Lukas Panzenboeck</investigator_title>
  </responsible_party>
  <keyword>spinal fusion</keyword>
  <keyword>topical antibiotics</keyword>
  <keyword>vancomycin</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

